Gene Therapy For Visual Impairment
By: Mark Burnsy
In modern society where most people are educated, eyesight problems inevitably proliferate, due to the fact that they have spent more time in reading. TV and computers are also incentives of the skyrocketed eyesight problems. Owing to the invention of eyeglasses and contact lenses, people with nearsightedness, farsightedness, astigmatism and presbyopia are able to view a clear world as well. Additionally, fast developed, eyeglass manufactures achieve advancement in glare reduction and unwanted wavelengths of light elimination.
However, eyeglasses and contacts can not serve as helps for vision improvement of people suffering from eye diseases, such as Macular Degeneration and Diabetic Retinopathy. Recently, a medical treatment is developed, which is also able to treat visual impairments. Avastin is a drug that was originally used in Colo-rectal cancer treatments but is found to have an ability to improve the vision in patients with Macular Degeneration, Diabetic Retinopathy and other vascular related retinal diseases. What's more, many other new drugs are brought about in succession as well, for example, the non steroidal anti inflammatory drugs can reduce retinal inflammation and cyst formations.
There are some people whose eye diseases arise from within the patients, genetic and congenital disorders. They pose a great challenge to eye doctors and surgeons. Luckily, gene therapy is found to be able to dramatically improve those patients' vision. The procedure is performed at the Scheie Eye Institute in Philadelphia and the patients formerly suffering from Leber's Congenital Amaurosis claim that he could read letters on an eye chart already after such a procedure. Then the news was published in the New England Journal of Medicine, on which the cause of Leber's Congenital Amaurosis and how the surgery achieves an success are recorded. It is stated that a lack of RPE 65 gene prevents protein production which is required for the retinal tissue to absorb and process the light into vision. A normal RPE is injected in the gene therapy to restore the protein production. After two weeks, the patients can mostly view more clearly than they did before. Possible complications of gene therapy include sensitivity to light.
In spit that it is just a successful case of Leber's Congenital Amaurosis treatment, it gives hopes to other eye diseases originated from gene disorders. Researches concerned are under procession. The application of gene therapy in visual impairment will be a great success in the near future.
Tuesday, October 26, 2010
Sunday, October 17, 2010
NeoVista Presents One-Year Study Results of Novel Therapy for Treatment of Neovascular Age-Related Macular Degeneration
NeoVista, Inc. made public today at the American Academy of Ophthalmology meeting the company’s one-year results from their MERITAGE Study. This study was designed to examine NeoVista’s novel Epimacular Brachytherapy procedure when used in patients who require chronic therapy with anti-VEGF agents on an ongoing basis to control Neovascular Age-Related Macular Degeneration (Wet AMD). The study enrolled patients who had as many as 38 prior injections of anti-VEGF therapy before receiving Epimacular Brachytherapy. The study population had a trend toward losing vision, even with regular anti-VEGF therapy in the year prior to enrollment. Prior to entry into the study, all patients were required to have received a loading dose of 3 monthly anti-VEGF injections and then a minimum of 5 additional injections in the 12 months preceding enrollment or 3 injections in the 6 months preceding enrollment. This ensured that the full benefit of anti-VEGF therapy was realized prior to entry into the study.
Study results (n=53) to date suggest that a single procedure of Epimacular Brachytherapy can stabilize visual acuity in a majority of this patient population (79%) while decreasing the number of anti-VEGF injections required. Most importantly, 47% of patients enrolled in the study experienced some improvement in their visual acuity while 10% of patients gained 15 or more letters of visual acuity at 12 months. This improvement is significant in patients that have been receiving chronic anti-VEGF treatment with no vision improvement in the year prior to enrollment, as compared to all other trials that are treating patients with newly onset disease.
The study results also pointed to a favorable trend with respect to a reduced number of anti-VEGF injections following delivery of Epimacular Brachytherapy (mean of 3.9) versus the period of time leading up to Epimacular Brachytherapy intervention (mean of 12.3). In addition, 25% of patients remained injection-free at 12 months following the Epimacular Brachytherapy procedure.
“MERITAGE is the first of its kind study designed to evaluate the potential role of the NeoVista device in treating chronic disease and decreasing the burden of treatment while maintaining or improving visual acuity,” said John N. Hendrick, President and CEO of NeoVista. “Data from recent randomized trials suggest that most patients suffering from Neovascular AMD will require anti-VEGF treatment on an ongoing basis for an indefinite period of time. We are very excited that our procedure, Epimacular Brachytherapy, not only has the potential to significantly decrease the number of injections administered but may also improve visual acuity in a significant percentage of this patient population.”
In contrast to other forms of radiation therapy for Neovascular AMD, NeoVista’s approach delivers a focused dose of energy directly to the wet AMD lesion without damaging the adjacent healthy retinal vasculature. Utilizing strontium 90, the targeted energy is delivered to a an area up to 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal and highly controlled to a local area. The effective dose to the entire body from NeoVista’s device is less than that from a typical chest x-ray. There were a limited number of adverse events in the trial, which were related to the surgical vitrectomy procedure, rather than Epimacular Brachytherapy.
The MERITAGE Study was conducted in two centers in the Unites States, one center in the United Kingdom, and two centers in Israel. Principal investigators were Pravin U. Dugel (USA), Michael D. Bennett (USA), Timothy L. Jackson (UK), Adiel Barack (Israel), and Dov Weinberger (Israel). The data was presented by Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, Phoenix, AZ. “The potential of this treatment is enormous,” said Dr. Dugel, “as this patient population represents the majority of patients that I see in my clinic each and every day. I believe that Epimacular Brachytherapy, unlike anti-VEGF therapy alone, offers a broad spectrum of activity and may therefore inhibit multiple disease processes involved in the pathology of wet AMD. To observe not only a reduction in treatment burden, but also an improvement in visual acuity in almost half of these difficult to treat patients at the one year mark is quite encouraging.”
NeoVista completed enrollment in the company’s first pivotal trial, CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy). CABERNET is a multicenter, randomized, controlled study that has enrolled over 490 subjects at 45 sites worldwide, and is evaluating the safety and efficacy of NeoVista’s therapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis® (ranibizumab) versus Lucentis alone.
A second pivotal trial MERLOT (Macular EpiRetinal Brachytherapy versus Lucentis® Only Treatment), sponsored by King’s College Hospital, London, England, (Principal Investigator-Mr. Tim Jackson), is being conducted in 20 centers throughout the United Kingdom. MERLOT is also a randomized, controlled study, with targeted patient enrollment of 363 subjects. This study is analyzing the effects of Epimacular Brachytherapy used concomitantly with as needed Lucentis injections versus continued Lucentis therapy alone, in patients who require chronic therapy with anti-VEGF agents on an ongoing basis to control Wet AMD.
About NeoVista, Inc.
NeoVista, Inc. is a privately held medical device company based in Newark, California. The company’s first commercial product, VIDION® ANV® Therapy System, is cleared for commercial use in all markets that accept a CE Mark.
For more information about the company, or this novel therapy, please visit the company’s Web site at www.neovistainc.com.
# # #
Vocus©Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Movie: Twelve Kingdoms – Chapter 7 – Reflection http://bit.ly/9KqKJi – by kitanoau (Kitano Holdings P/L)
The Twelve Kingdoms episode 39-1 (Audio English) /45
The Twelve Kingdoms episode 39-1 (Audio English) /45
Related Posts:
* Horror Movie Freak Author Don Sumner Presents the Horror Movies to Watch Over the 10 Days to Halloween
* Freedom: A Novel (Oprah’s Book Club)
* Blood Thinner OK for Superficial Leg Clots: Study
* Monday’s local golf results
* Full Metal Panic! (novel) Volume 1: Fighting Boy Meets Girl
Tagged as: AgeRelated, Degeneration, Macular, Neovascular, NeoVista, novel, OneYear, presents..., results, Study, Therapy, Treatment
{ 25 comments… read them below or add one }
MrJustletmeseeit October 16, 2010 at 12:39 AM
@gr8Sweetfox Ok, what if we stuff the nuke with pixies and unicorns?
Reply
gr8Sweetfox October 16, 2010 at 1:23 AM
@MrJustletmeseeit that wouldnt happen. at least the trees.. i mean this special trees are never affected.. they seem to be impossible to destroy
Reply
MrJustletmeseeit October 16, 2010 at 1:55 AM
@gr8Sweetfox what if the nuke slips thru and detonates while tentei is yawning? or getting it on with some hot goddess…
Reply
RokenMusic October 16, 2010 at 1:56 AM
@gr8Sweetfox As for your question about the princess’s palace song. I do not believe an official attempt of dubbing it into English was ever made. There might be fan made videos floating out there. I recommend you search the first line of the song’s lyrics for these. Good luck.
Reply
RokenMusic October 16, 2010 at 2:33 AM
@gr8Sweetfox 12 Kingdoms is very unique in that it is what I would like to call “a Fantasy Opera”, in which the characters are vivid and the central storyline lives within an epic world of continuous stories. This kind of anime are very hard sells because it requires the anime studios to invest heavily and risk utter failure. However, there are a few out there that are on similar caliber. One is Legend of Galactic Heroes. Unfortunately it is science fiction rather than fantasy.
Reply
gr8Sweetfox October 16, 2010 at 3:00 AM
@RokenMusic something like 12 kingdoms with anime?
ps, you were fast. And maybe you know something about the english dubbed version of Sho something. You know that song about a doll… maybe you know something i want it in english so badly ugh i would even pay for it ;__;
Reply
RokenMusic October 16, 2010 at 3:29 AM
@gr8Sweetfox EVA: Neon Genesis Evangelion
LoGH: Legend of Galactic Heroes
Ronin Kenshin
Cowboy Bebop
Trigun
Black Lagoon
and the list goes on depending on your tastes.
Reply
gr8Sweetfox October 16, 2010 at 3:58 AM
@RokenMusic ok , what is EVA, LoGH, and etc. ?
Reply
gr8Sweetfox October 16, 2010 at 4:49 AM
@MrJustletmeseeit nah it would not. Tentei protects their world.
Reply
MrJustletmeseeit October 16, 2010 at 5:16 AM
man… one of todays nukes would take that whole world out =(((
Reply
maihoua19 October 16, 2010 at 6:01 AM
i always felt exciting watching this movie and love it
Reply
endlesssonata October 16, 2010 at 6:25 AM
I love all the Oooohhhh and Aaaahhhhh. So freaking cool!
Reply
endlesssonata October 16, 2010 at 6:55 AM
WOW this one is my favorite ep ever! Youko’s entre is soooo coolll. Now that IS how a queen reveal herself!
Reply
Goatmon October 16, 2010 at 7:43 AM
Youko is the boss, and she’s layin’ down the law.
Reply
Goatmon October 16, 2010 at 7:49 AM
@chebozz Fantasy/Adventure?
Reply
ZRaya99 October 16, 2010 at 8:27 AM
i like how they all laught
Reply
enariuzai October 16, 2010 at 8:51 AM
早く続きが観たいです、続編が再開されたみたいだし＾＾
Reply
afny19 October 16, 2010 at 9:11 AM
if the real world have ruler like this, this world can be a better place… so wise and noble even if that person use to be just a commoner ^^,
Reply
brokenating October 16, 2010 at 10:00 AM
i really love this episode! :D
Reply
zeroEDJE October 16, 2010 at 10:08 AM
For a second there I thought we were going to see the intro.
Reply
chebozz October 16, 2010 at 10:33 AM
hmmm…what is the genre of this anime??
Reply
mancdg627aol October 16, 2010 at 11:26 AM
I love watching this episode over and over again it’s so cool when keiki showed up and youko questioned general jinrai hahaha… The best anime i watched on its genre… I will buy the books an read it…. ^^
Reply
RokenMusic October 16, 2010 at 12:05 PM
@gabaroo59: No, not really. Twelve kingdoms is one of the best light novel series and anime series. Up there with EVA, LoGH, and etc.
I’m surprised that they didn’t do a half bad job at dubbing this anime. The translation is pretty accurate to the original. Although Yoko’s voice is supposed to be more boyish.
Reply
bollywoodgirl21 October 16, 2010 at 12:16 PM
I love yokos speach in the beginning, she just rules!!!
Reply
tearsangelz October 16, 2010 at 12:54 PM
i totally agree<3 all the beasts in this anime is just so awesome!
Reply
Cancel reply
Leave a Comment
Name *
E-mail *
Website
Get a new challenge Get an audio challengeGet a visual challenge Help
Previous post: “Hulk” the Incredible Guide
Next post: “I’ve Forgotten Everything I Learned in School!”: A Refresher Course to Help You Reclaim Your Education
Recent Posts
*
Pokémon Apokélypse: Live Action Trailer HDPokémon Apokélypse: Live Action Trailer HD
Pokémon Apokélypse: Live Action Trailer… »
*
New York Comic Con: V, Vampire Diaries and Nikita Take ManhattanNew York Comic Con: V, Vampire Diaries and Nikita Take Manhattan
New York Comic Con: V, Vampire Diaries and Nikita Take Manhattan After a year and a half… »
*
Where can I find english dub episodes of sorcerous stabber orphen and MAR?Where can I find english dub episodes of sorcerous stabber orphen and MAR?
Question by hannahhannahhowhow: Where can I find english dub episodes of sorcerous stabber orphen and… »
*
Air Gear, Vol. 1Air Gear, Vol. 1
Air Gear, Vol. 1 ISBN13: 9780345492784Condition: NewNotes: BUY WITH CONFIDENCE, Over one… »
*
Confirmed Speakers Announced for Exhibition and Convention Executives Forum (ECEF) 2011Confirmed Speakers Announced for Exhibition and Convention Executives Forum (ECEF) 2011
Confirmed Speakers Announced for Exhibition and Convention Executives Forum (ECEF) 2011 The… »
*
“I’ve Forgotten Everything I Learned in School!”: A Refresher Course to Help You Reclaim Your Education“I’ve Forgotten Everything I Learned in School!”: A Refresher Course to Help You Reclaim Your Education
"I've Forgotten Everything I Learned in School!": A Refresher Course to Help You Reclaim Your… »
*
NeoVista Presents One-Year Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular DegenerationNeoVista Presents One-Year Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular Degeneration
NeoVista Presents One-Year Study Results of Novel Therapy for the Treatment of Neovascular Age-Related… »
Study results (n=53) to date suggest that a single procedure of Epimacular Brachytherapy can stabilize visual acuity in a majority of this patient population (79%) while decreasing the number of anti-VEGF injections required. Most importantly, 47% of patients enrolled in the study experienced some improvement in their visual acuity while 10% of patients gained 15 or more letters of visual acuity at 12 months. This improvement is significant in patients that have been receiving chronic anti-VEGF treatment with no vision improvement in the year prior to enrollment, as compared to all other trials that are treating patients with newly onset disease.
The study results also pointed to a favorable trend with respect to a reduced number of anti-VEGF injections following delivery of Epimacular Brachytherapy (mean of 3.9) versus the period of time leading up to Epimacular Brachytherapy intervention (mean of 12.3). In addition, 25% of patients remained injection-free at 12 months following the Epimacular Brachytherapy procedure.
“MERITAGE is the first of its kind study designed to evaluate the potential role of the NeoVista device in treating chronic disease and decreasing the burden of treatment while maintaining or improving visual acuity,” said John N. Hendrick, President and CEO of NeoVista. “Data from recent randomized trials suggest that most patients suffering from Neovascular AMD will require anti-VEGF treatment on an ongoing basis for an indefinite period of time. We are very excited that our procedure, Epimacular Brachytherapy, not only has the potential to significantly decrease the number of injections administered but may also improve visual acuity in a significant percentage of this patient population.”
In contrast to other forms of radiation therapy for Neovascular AMD, NeoVista’s approach delivers a focused dose of energy directly to the wet AMD lesion without damaging the adjacent healthy retinal vasculature. Utilizing strontium 90, the targeted energy is delivered to a an area up to 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal and highly controlled to a local area. The effective dose to the entire body from NeoVista’s device is less than that from a typical chest x-ray. There were a limited number of adverse events in the trial, which were related to the surgical vitrectomy procedure, rather than Epimacular Brachytherapy.
The MERITAGE Study was conducted in two centers in the Unites States, one center in the United Kingdom, and two centers in Israel. Principal investigators were Pravin U. Dugel (USA), Michael D. Bennett (USA), Timothy L. Jackson (UK), Adiel Barack (Israel), and Dov Weinberger (Israel). The data was presented by Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, Phoenix, AZ. “The potential of this treatment is enormous,” said Dr. Dugel, “as this patient population represents the majority of patients that I see in my clinic each and every day. I believe that Epimacular Brachytherapy, unlike anti-VEGF therapy alone, offers a broad spectrum of activity and may therefore inhibit multiple disease processes involved in the pathology of wet AMD. To observe not only a reduction in treatment burden, but also an improvement in visual acuity in almost half of these difficult to treat patients at the one year mark is quite encouraging.”
NeoVista completed enrollment in the company’s first pivotal trial, CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy). CABERNET is a multicenter, randomized, controlled study that has enrolled over 490 subjects at 45 sites worldwide, and is evaluating the safety and efficacy of NeoVista’s therapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis® (ranibizumab) versus Lucentis alone.
A second pivotal trial MERLOT (Macular EpiRetinal Brachytherapy versus Lucentis® Only Treatment), sponsored by King’s College Hospital, London, England, (Principal Investigator-Mr. Tim Jackson), is being conducted in 20 centers throughout the United Kingdom. MERLOT is also a randomized, controlled study, with targeted patient enrollment of 363 subjects. This study is analyzing the effects of Epimacular Brachytherapy used concomitantly with as needed Lucentis injections versus continued Lucentis therapy alone, in patients who require chronic therapy with anti-VEGF agents on an ongoing basis to control Wet AMD.
About NeoVista, Inc.
NeoVista, Inc. is a privately held medical device company based in Newark, California. The company’s first commercial product, VIDION® ANV® Therapy System, is cleared for commercial use in all markets that accept a CE Mark.
For more information about the company, or this novel therapy, please visit the company’s Web site at www.neovistainc.com.
# # #
Vocus©Copyright 1997-2010, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Movie: Twelve Kingdoms – Chapter 7 – Reflection http://bit.ly/9KqKJi – by kitanoau (Kitano Holdings P/L)
The Twelve Kingdoms episode 39-1 (Audio English) /45
The Twelve Kingdoms episode 39-1 (Audio English) /45
Related Posts:
* Horror Movie Freak Author Don Sumner Presents the Horror Movies to Watch Over the 10 Days to Halloween
* Freedom: A Novel (Oprah’s Book Club)
* Blood Thinner OK for Superficial Leg Clots: Study
* Monday’s local golf results
* Full Metal Panic! (novel) Volume 1: Fighting Boy Meets Girl
Tagged as: AgeRelated, Degeneration, Macular, Neovascular, NeoVista, novel, OneYear, presents..., results, Study, Therapy, Treatment
{ 25 comments… read them below or add one }
MrJustletmeseeit October 16, 2010 at 12:39 AM
@gr8Sweetfox Ok, what if we stuff the nuke with pixies and unicorns?
Reply
gr8Sweetfox October 16, 2010 at 1:23 AM
@MrJustletmeseeit that wouldnt happen. at least the trees.. i mean this special trees are never affected.. they seem to be impossible to destroy
Reply
MrJustletmeseeit October 16, 2010 at 1:55 AM
@gr8Sweetfox what if the nuke slips thru and detonates while tentei is yawning? or getting it on with some hot goddess…
Reply
RokenMusic October 16, 2010 at 1:56 AM
@gr8Sweetfox As for your question about the princess’s palace song. I do not believe an official attempt of dubbing it into English was ever made. There might be fan made videos floating out there. I recommend you search the first line of the song’s lyrics for these. Good luck.
Reply
RokenMusic October 16, 2010 at 2:33 AM
@gr8Sweetfox 12 Kingdoms is very unique in that it is what I would like to call “a Fantasy Opera”, in which the characters are vivid and the central storyline lives within an epic world of continuous stories. This kind of anime are very hard sells because it requires the anime studios to invest heavily and risk utter failure. However, there are a few out there that are on similar caliber. One is Legend of Galactic Heroes. Unfortunately it is science fiction rather than fantasy.
Reply
gr8Sweetfox October 16, 2010 at 3:00 AM
@RokenMusic something like 12 kingdoms with anime?
ps, you were fast. And maybe you know something about the english dubbed version of Sho something. You know that song about a doll… maybe you know something i want it in english so badly ugh i would even pay for it ;__;
Reply
RokenMusic October 16, 2010 at 3:29 AM
@gr8Sweetfox EVA: Neon Genesis Evangelion
LoGH: Legend of Galactic Heroes
Ronin Kenshin
Cowboy Bebop
Trigun
Black Lagoon
and the list goes on depending on your tastes.
Reply
gr8Sweetfox October 16, 2010 at 3:58 AM
@RokenMusic ok , what is EVA, LoGH, and etc. ?
Reply
gr8Sweetfox October 16, 2010 at 4:49 AM
@MrJustletmeseeit nah it would not. Tentei protects their world.
Reply
MrJustletmeseeit October 16, 2010 at 5:16 AM
man… one of todays nukes would take that whole world out =(((
Reply
maihoua19 October 16, 2010 at 6:01 AM
i always felt exciting watching this movie and love it
Reply
endlesssonata October 16, 2010 at 6:25 AM
I love all the Oooohhhh and Aaaahhhhh. So freaking cool!
Reply
endlesssonata October 16, 2010 at 6:55 AM
WOW this one is my favorite ep ever! Youko’s entre is soooo coolll. Now that IS how a queen reveal herself!
Reply
Goatmon October 16, 2010 at 7:43 AM
Youko is the boss, and she’s layin’ down the law.
Reply
Goatmon October 16, 2010 at 7:49 AM
@chebozz Fantasy/Adventure?
Reply
ZRaya99 October 16, 2010 at 8:27 AM
i like how they all laught
Reply
enariuzai October 16, 2010 at 8:51 AM
早く続きが観たいです、続編が再開されたみたいだし＾＾
Reply
afny19 October 16, 2010 at 9:11 AM
if the real world have ruler like this, this world can be a better place… so wise and noble even if that person use to be just a commoner ^^,
Reply
brokenating October 16, 2010 at 10:00 AM
i really love this episode! :D
Reply
zeroEDJE October 16, 2010 at 10:08 AM
For a second there I thought we were going to see the intro.
Reply
chebozz October 16, 2010 at 10:33 AM
hmmm…what is the genre of this anime??
Reply
mancdg627aol October 16, 2010 at 11:26 AM
I love watching this episode over and over again it’s so cool when keiki showed up and youko questioned general jinrai hahaha… The best anime i watched on its genre… I will buy the books an read it…. ^^
Reply
RokenMusic October 16, 2010 at 12:05 PM
@gabaroo59: No, not really. Twelve kingdoms is one of the best light novel series and anime series. Up there with EVA, LoGH, and etc.
I’m surprised that they didn’t do a half bad job at dubbing this anime. The translation is pretty accurate to the original. Although Yoko’s voice is supposed to be more boyish.
Reply
bollywoodgirl21 October 16, 2010 at 12:16 PM
I love yokos speach in the beginning, she just rules!!!
Reply
tearsangelz October 16, 2010 at 12:54 PM
i totally agree<3 all the beasts in this anime is just so awesome!
Reply
Cancel reply
Leave a Comment
Name *
E-mail *
Website
Get a new challenge Get an audio challengeGet a visual challenge Help
Previous post: “Hulk” the Incredible Guide
Next post: “I’ve Forgotten Everything I Learned in School!”: A Refresher Course to Help You Reclaim Your Education
Recent Posts
*
Pokémon Apokélypse: Live Action Trailer HDPokémon Apokélypse: Live Action Trailer HD
Pokémon Apokélypse: Live Action Trailer… »
*
New York Comic Con: V, Vampire Diaries and Nikita Take ManhattanNew York Comic Con: V, Vampire Diaries and Nikita Take Manhattan
New York Comic Con: V, Vampire Diaries and Nikita Take Manhattan After a year and a half… »
*
Where can I find english dub episodes of sorcerous stabber orphen and MAR?Where can I find english dub episodes of sorcerous stabber orphen and MAR?
Question by hannahhannahhowhow: Where can I find english dub episodes of sorcerous stabber orphen and… »
*
Air Gear, Vol. 1Air Gear, Vol. 1
Air Gear, Vol. 1 ISBN13: 9780345492784Condition: NewNotes: BUY WITH CONFIDENCE, Over one… »
*
Confirmed Speakers Announced for Exhibition and Convention Executives Forum (ECEF) 2011Confirmed Speakers Announced for Exhibition and Convention Executives Forum (ECEF) 2011
Confirmed Speakers Announced for Exhibition and Convention Executives Forum (ECEF) 2011 The… »
*
“I’ve Forgotten Everything I Learned in School!”: A Refresher Course to Help You Reclaim Your Education“I’ve Forgotten Everything I Learned in School!”: A Refresher Course to Help You Reclaim Your Education
"I've Forgotten Everything I Learned in School!": A Refresher Course to Help You Reclaim Your… »
*
NeoVista Presents One-Year Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular DegenerationNeoVista Presents One-Year Study Results of Novel Therapy for the Treatment of Neovascular Age-Related Macular Degeneration
NeoVista Presents One-Year Study Results of Novel Therapy for the Treatment of Neovascular Age-Related… »
Sunday, October 10, 2010
Zeaxanthin For Macular Degeneration Prevention and Treatment for Dry AMD
by Forrestal
Most ophthalmologists recommend the antioxidants lutein and zeaxanthin for macular degeneration that is age related, commonly referred to as AMD. It is unusual for doctor’s to recommend nutritional supplements of any kind, unless a person has an outright deficiency, but AMD is a unique condition.
There are no effective treatments for one type of AMD (dry), but there are some partially effective treatments for wet AMD. Together, these two are the major causes of blindness in the elderly. The wet form is the most severe, if not treated early.
In wet AMD, blood vessels grow up and behind the retina, an area responsible for gathering light and transmitting signals to the brain, resulting in sight. The blood vessels often rupture and leak blood and protein below the macula, a very sensitive area within the retina.
Eventually, bleeding, leaking and scarring causes irreversible damage to the light receptors (rods and cones). Rapid vision loss is experienced if it is left untreated. Laser treatment and drugs that inhibit blood vessel growth are usually recommended.
Generally, doctors recommend lutein and zeaxanthin for macular degeneration that is of the dry type. Dry AMD is much more common than wet. It is caused by a build up of yellow deposits called drusen on the retina.
In nature lutein and zeaxanthin are pigments or colors. They are normally present in the retina, with zeaxanthin being concentrated in the macula and lutein more highly concentrated in the periphery of the retina. There roles within the eye are not well understood, but they seem to help reduce or prevent the build up of drusen.
Drusen is similar in composition to the deposits that are found in the brains of Alzheimer’s patients and the plaque that is present in atherosclerosis. People with either of those two conditions have a higher risk of developing dry AMD.
Some doctors recommend taking lutein and zeaxanthin for macular degeneration prevention, particularly to their patients that have a family history of the disease. But, since the drusen are similar to the deposits that cause Alzheimer’s and heart disease, other antioxidants may be beneficial, as well.
Curcumin, an antioxidant present in the spice turmeric, is currently being studied for its benefit in Alzheimer’s disease. Not only does it prevent the accumulation of the plaque, it breaks it up. It might be able to break up the drusen in AMD, too.
One study indicates that the ideal combination of nutrients is omega 3 fatty acids, beta carotene, vitamin E, lutein and zeaxanthin for macular degeneration. Omega 3 fatty acids, particularly DHA, are the most abundant fatty acids present in the retina. Beta-carotene is converted by the body to vitamin A, which is essential for good vision. Vitamin E is well-known for its antioxidant activity.
Prevention is worth a pound of cure, they say. In order to prevent AMD, people should lower their total fat intake, and increase their nutrient intake. This may help reduce the risk of many other diseases, as well. Taking zeaxanthin for macular degeneration prevention is a good idea. Taking a multi-nutritional supplement that contains it, is a great one.
Most ophthalmologists recommend the antioxidants lutein and zeaxanthin for macular degeneration that is age related, commonly referred to as AMD. It is unusual for doctor’s to recommend nutritional supplements of any kind, unless a person has an outright deficiency, but AMD is a unique condition.
There are no effective treatments for one type of AMD (dry), but there are some partially effective treatments for wet AMD. Together, these two are the major causes of blindness in the elderly. The wet form is the most severe, if not treated early.
In wet AMD, blood vessels grow up and behind the retina, an area responsible for gathering light and transmitting signals to the brain, resulting in sight. The blood vessels often rupture and leak blood and protein below the macula, a very sensitive area within the retina.
Eventually, bleeding, leaking and scarring causes irreversible damage to the light receptors (rods and cones). Rapid vision loss is experienced if it is left untreated. Laser treatment and drugs that inhibit blood vessel growth are usually recommended.
Generally, doctors recommend lutein and zeaxanthin for macular degeneration that is of the dry type. Dry AMD is much more common than wet. It is caused by a build up of yellow deposits called drusen on the retina.
In nature lutein and zeaxanthin are pigments or colors. They are normally present in the retina, with zeaxanthin being concentrated in the macula and lutein more highly concentrated in the periphery of the retina. There roles within the eye are not well understood, but they seem to help reduce or prevent the build up of drusen.
Drusen is similar in composition to the deposits that are found in the brains of Alzheimer’s patients and the plaque that is present in atherosclerosis. People with either of those two conditions have a higher risk of developing dry AMD.
Some doctors recommend taking lutein and zeaxanthin for macular degeneration prevention, particularly to their patients that have a family history of the disease. But, since the drusen are similar to the deposits that cause Alzheimer’s and heart disease, other antioxidants may be beneficial, as well.
Curcumin, an antioxidant present in the spice turmeric, is currently being studied for its benefit in Alzheimer’s disease. Not only does it prevent the accumulation of the plaque, it breaks it up. It might be able to break up the drusen in AMD, too.
One study indicates that the ideal combination of nutrients is omega 3 fatty acids, beta carotene, vitamin E, lutein and zeaxanthin for macular degeneration. Omega 3 fatty acids, particularly DHA, are the most abundant fatty acids present in the retina. Beta-carotene is converted by the body to vitamin A, which is essential for good vision. Vitamin E is well-known for its antioxidant activity.
Prevention is worth a pound of cure, they say. In order to prevent AMD, people should lower their total fat intake, and increase their nutrient intake. This may help reduce the risk of many other diseases, as well. Taking zeaxanthin for macular degeneration prevention is a good idea. Taking a multi-nutritional supplement that contains it, is a great one.
Monday, October 4, 2010
Combination PDT, anti-VEG effective for choroidal neovascularization due to AMD
October 4, 2010
A customized combination of photodynamic therapy and intravitreal ranibizumab treatment for choroidal neovascularization due to age-related macular degeneration achieved good visual results with a decreased need for re-treatment, a study found.
"Combined customized PDT and ranibizumab treatment can achieve visual results similar to those obtained with intravitreal monotherapy with the advantage of fewer intravitreous injections and reduced potential for adverse effects," the study said.
In the nonrandomized, prospective, interventional study, 53 eyes of 53 patients with subfoveal and juxtafoveal choroidal neovascularization secondary to AMD were treated with PDT and intravitreal Lucentis (ranibizumab, Genentech).
At the end of the 12-month follow-up period, subjects' mean visual acuity had improved by 7.2 letters, and 78.8% maintained or improved their initial vision.
"The central retinal thickness and choroidal neovascularization size decreased to 118 µm and 0.26 disc areas, respectively, from baseline to 12 months," the study authors said.
Sixty-five PDT treatments (mean of 1.22 per patient) were performed, and 126 doses of ranibizumab were injected (mean of 2.37 per patient).
In 21 cases, only a single initial dose of PDT and ranibizumab was required.
A customized combination of photodynamic therapy and intravitreal ranibizumab treatment for choroidal neovascularization due to age-related macular degeneration achieved good visual results with a decreased need for re-treatment, a study found.
"Combined customized PDT and ranibizumab treatment can achieve visual results similar to those obtained with intravitreal monotherapy with the advantage of fewer intravitreous injections and reduced potential for adverse effects," the study said.
In the nonrandomized, prospective, interventional study, 53 eyes of 53 patients with subfoveal and juxtafoveal choroidal neovascularization secondary to AMD were treated with PDT and intravitreal Lucentis (ranibizumab, Genentech).
At the end of the 12-month follow-up period, subjects' mean visual acuity had improved by 7.2 letters, and 78.8% maintained or improved their initial vision.
"The central retinal thickness and choroidal neovascularization size decreased to 118 µm and 0.26 disc areas, respectively, from baseline to 12 months," the study authors said.
Sixty-five PDT treatments (mean of 1.22 per patient) were performed, and 126 doses of ranibizumab were injected (mean of 2.37 per patient).
In 21 cases, only a single initial dose of PDT and ranibizumab was required.
Saturday, September 18, 2010
Advanced Cell Technology Obtains Broad Patent covering use of Stem Cell
Sep 14, 2010 by Advanced Cell Techno;ogy
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will be issued U.S. Patent Numbers 7,795,025 and 7,794,704 on Tuesday, September 14th, which continue to extend the company's patent portfolio covering its retinal pigment epithelial (RPE) cell programs. In particular, the claims that will issue in patent number 7,794,704 broadly cover methods for treating retinal degeneration using human RPE cells differentiated from human embryonic stem cells (hESCs). Issuing with 68 claims, this patent covers methods of treatment with hESC-derived RPE cells that includes, but is not limited to, Stargardt's disease, retinitis pigmentosa, and macular degeneration. The 41 claims issuing in US Patent 7,795,025 contribute to the development of the company's protection of the processes for manufacturing RPE cells from human ES cells. The patent covers fundamental methods for generating transplantable cells for treatment of human patients.
"Another wonderful milestone for ACT! These patents continue the recognition of the inventions and innovations resulting from our scientific team's ongoing research, and further protects the platform technology underlying our RPE program, one of our key therapeutic programs," said William M. Caldwell IV, ACT's Chairman and CEO. "A valuable addition to our strong intellectual property portfolio, these patents should help position ACT as the dominant player in this potentially very large market. Our RPE technology is safe and scalable, and has tremendous potential for treating some 200 or more diseases of the retina."
"ACT is developing first-in-class treatments for degenerative disorders of the retina," said Robert Lanza, M.D., ACT's Chief Scientific Officer. "The use of RPE cells created from human embryonic stem cells should open the door to potential treatments for many diseases of the retina that impact sight. According to the World Health Organization, macular degeneration alone is known to affect 30-40 million people worldwide, and this represents only a handful of the 200 diseases that may be treated using our RPE cells. We have worked hard to develop an efficient method for producing a renewable source of transplantable RPE cells that can be used to target diseases such as Stargardt's Disease and Age-related Macular Degeneration. For many of these patients there are no available treatments. We have demonstrated that our stem cell-derived RPE cells can rescue visual function in animals that otherwise would have gone blind. We are looking forward to starting our clinical trials with the hope that these cells will be similarly efficacious in patients."
"We believe that these patents are especially important as they extend the company's patent coverage of the scalable manufacturing of human RPE cells for therapeutic use, which are core to our technology and product portfolio," continued Mr. Caldwell. "This IP further expands our patent estate with respect to protecting the use of RPE cells in a wide range of treatments, offering additional validation of the strength and breadth of our patent portfolio. This development also dovetails nicely with the prospect of initiating our human clinical trial for our RPE program. We are optimistic that the methods-of-treatments and the culturing processes covered by these two new patents, along with the Company's proprietary detection technique for final product release, will establish a formidable barrier to entry for any potential competitors. Once we have begun to treat Stargardt patients, we plan to initiate another clinical trial relating to the use of RPE cells in the treatment of dry Age-Related Macular Degeneration (AMD). At present there is no approved treatment for dry AMD, despite the fact that it represents a $20-30 billion potential market."
ACT's Single Blastomere technology used for isolating hESCs does not require the destruction of embryos. The RPE and other hESC-derived cells the company intends to produce for clinical use all begin with these "embryo-safe" stem cells. ACT does not rely on government funding for any of its research or development efforts, and accordingly has not been impacted by the recent court injunction against federal funding of hESC research. Nevertheless, the company's hESC lines and cells made for those lines (such as RPE cells) should fall outside the scope of the court order. While the injunction has been stayed, it is widely believed that this is only a temporary reprieve, with a permanent injunction a real possibility perhaps as early as the end of this month. Should that come to pass, ACT stands ready to offer its human stem cell lines to the research community, pending their approval by the National Institutes of Health (NIH).
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "broad," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, scope and enforceability of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will be issued U.S. Patent Numbers 7,795,025 and 7,794,704 on Tuesday, September 14th, which continue to extend the company's patent portfolio covering its retinal pigment epithelial (RPE) cell programs. In particular, the claims that will issue in patent number 7,794,704 broadly cover methods for treating retinal degeneration using human RPE cells differentiated from human embryonic stem cells (hESCs). Issuing with 68 claims, this patent covers methods of treatment with hESC-derived RPE cells that includes, but is not limited to, Stargardt's disease, retinitis pigmentosa, and macular degeneration. The 41 claims issuing in US Patent 7,795,025 contribute to the development of the company's protection of the processes for manufacturing RPE cells from human ES cells. The patent covers fundamental methods for generating transplantable cells for treatment of human patients.
"Another wonderful milestone for ACT! These patents continue the recognition of the inventions and innovations resulting from our scientific team's ongoing research, and further protects the platform technology underlying our RPE program, one of our key therapeutic programs," said William M. Caldwell IV, ACT's Chairman and CEO. "A valuable addition to our strong intellectual property portfolio, these patents should help position ACT as the dominant player in this potentially very large market. Our RPE technology is safe and scalable, and has tremendous potential for treating some 200 or more diseases of the retina."
"ACT is developing first-in-class treatments for degenerative disorders of the retina," said Robert Lanza, M.D., ACT's Chief Scientific Officer. "The use of RPE cells created from human embryonic stem cells should open the door to potential treatments for many diseases of the retina that impact sight. According to the World Health Organization, macular degeneration alone is known to affect 30-40 million people worldwide, and this represents only a handful of the 200 diseases that may be treated using our RPE cells. We have worked hard to develop an efficient method for producing a renewable source of transplantable RPE cells that can be used to target diseases such as Stargardt's Disease and Age-related Macular Degeneration. For many of these patients there are no available treatments. We have demonstrated that our stem cell-derived RPE cells can rescue visual function in animals that otherwise would have gone blind. We are looking forward to starting our clinical trials with the hope that these cells will be similarly efficacious in patients."
"We believe that these patents are especially important as they extend the company's patent coverage of the scalable manufacturing of human RPE cells for therapeutic use, which are core to our technology and product portfolio," continued Mr. Caldwell. "This IP further expands our patent estate with respect to protecting the use of RPE cells in a wide range of treatments, offering additional validation of the strength and breadth of our patent portfolio. This development also dovetails nicely with the prospect of initiating our human clinical trial for our RPE program. We are optimistic that the methods-of-treatments and the culturing processes covered by these two new patents, along with the Company's proprietary detection technique for final product release, will establish a formidable barrier to entry for any potential competitors. Once we have begun to treat Stargardt patients, we plan to initiate another clinical trial relating to the use of RPE cells in the treatment of dry Age-Related Macular Degeneration (AMD). At present there is no approved treatment for dry AMD, despite the fact that it represents a $20-30 billion potential market."
ACT's Single Blastomere technology used for isolating hESCs does not require the destruction of embryos. The RPE and other hESC-derived cells the company intends to produce for clinical use all begin with these "embryo-safe" stem cells. ACT does not rely on government funding for any of its research or development efforts, and accordingly has not been impacted by the recent court injunction against federal funding of hESC research. Nevertheless, the company's hESC lines and cells made for those lines (such as RPE cells) should fall outside the scope of the court order. While the injunction has been stayed, it is widely believed that this is only a temporary reprieve, with a permanent injunction a real possibility perhaps as early as the end of this month. Should that come to pass, ACT stands ready to offer its human stem cell lines to the research community, pending their approval by the National Institutes of Health (NIH).
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "broad," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, scope and enforceability of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Sunday, September 12, 2010
How to prevent age-related macular degeneration
by Dr Pandula Siribaddana
Age Related Macular Degeneration or ARMD is a common condition seen in the elderly population and can be named as one of the commonest causes of visual loss among the same age group. The condition is characterized by the gradual loss of central vision and could be recognized as having two major categories.
In one form, which is the ‘dry’ macular degeneration, the retina and the layer below in the back of the eye would be separated by cellular debris and in the second form, which is the ‘wet’ macular degeneration, the two layers will be separated by enlarging blood vessels under the retina. In both instances, the peripheral vision would be spared and therefore, these individuals would be able to carry out their daily activities, although the functions such as reading would be impaired to a significant extent.
How to prevent ARMD in the elderly?
The prevention strategies related to ARMD would include avoiding the risk factors which would cause the condition in the first place. Therefore, following prevention strategies can be named as the most useful in order to achieve better vision in the elderly age.
Control blood sugar levels
This has shown to have an influence in the manifestation of macular degeneration and since it is prevalent abundantly, adhering to good glycaemic control would be essential to reduce the disease burden of ARMD.
Avoid smoking
Among the many influences it makes on health, macular degeneration is one and therefore its avoidance would greatly help susceptible individuals to maintain better visual health. According to statistics, there seems to be a threefold risk among the smokers than in non-smokers to develop ARMD during the elderly life.
Control hypertension and cardiovascular diseases
Researchers have identified these two as influencing the occurrence of macular degeneration and controlling of the same would reduce the risk of ARMD in susceptible individuals.
Avoid direct sun light
Sun light, particularly the blue light in the sun’s rays, have shown to influence the functioning of the retina and thus can lead to the development of ARMD. Therefore, using special eye glasses and avoiding such exposure would be recommended for people whom are constantly at risk of being exposed.
Include carotenes in the diet
Carotenes containing foods or else supplements have shown to be effective to a certain extent in reducing the risk of macular degeneration and therefore steps should be taken to include such foods and to take a balanced diet as much as possible.
Add omega 3 fatty acids
Similar to carotenes, omega 3 fatty acids are suggested as being supportive in the prevention of ARMD and should be included in the diets of all ages.
Lastly, due to the fact that there are other factors which are not modifiable and may lead to the development of ARMD, it is always best to screen and initiate treatment as early as possible in order to prevent progression of the disease and to avoid the occurrence of complete blindness.
Age Related Macular Degeneration or ARMD is a common condition seen in the elderly population and can be named as one of the commonest causes of visual loss among the same age group. The condition is characterized by the gradual loss of central vision and could be recognized as having two major categories.
In one form, which is the ‘dry’ macular degeneration, the retina and the layer below in the back of the eye would be separated by cellular debris and in the second form, which is the ‘wet’ macular degeneration, the two layers will be separated by enlarging blood vessels under the retina. In both instances, the peripheral vision would be spared and therefore, these individuals would be able to carry out their daily activities, although the functions such as reading would be impaired to a significant extent.
How to prevent ARMD in the elderly?
The prevention strategies related to ARMD would include avoiding the risk factors which would cause the condition in the first place. Therefore, following prevention strategies can be named as the most useful in order to achieve better vision in the elderly age.
Control blood sugar levels
This has shown to have an influence in the manifestation of macular degeneration and since it is prevalent abundantly, adhering to good glycaemic control would be essential to reduce the disease burden of ARMD.
Avoid smoking
Among the many influences it makes on health, macular degeneration is one and therefore its avoidance would greatly help susceptible individuals to maintain better visual health. According to statistics, there seems to be a threefold risk among the smokers than in non-smokers to develop ARMD during the elderly life.
Control hypertension and cardiovascular diseases
Researchers have identified these two as influencing the occurrence of macular degeneration and controlling of the same would reduce the risk of ARMD in susceptible individuals.
Avoid direct sun light
Sun light, particularly the blue light in the sun’s rays, have shown to influence the functioning of the retina and thus can lead to the development of ARMD. Therefore, using special eye glasses and avoiding such exposure would be recommended for people whom are constantly at risk of being exposed.
Include carotenes in the diet
Carotenes containing foods or else supplements have shown to be effective to a certain extent in reducing the risk of macular degeneration and therefore steps should be taken to include such foods and to take a balanced diet as much as possible.
Add omega 3 fatty acids
Similar to carotenes, omega 3 fatty acids are suggested as being supportive in the prevention of ARMD and should be included in the diets of all ages.
Lastly, due to the fact that there are other factors which are not modifiable and may lead to the development of ARMD, it is always best to screen and initiate treatment as early as possible in order to prevent progression of the disease and to avoid the occurrence of complete blindness.
Wednesday, September 1, 2010
Limited Retinal Translocation for Wet Macular Degeneration
by Samantha Power
August 31st, 2010
Limited Retinal Translocation-Limited retinal translocation is another treatment aimed at wet macular degeneration. In this procedure the retina is actually moved somewhat to allow laser treatments to be applied more successfully to abnormal blood vessel growth. The procedure is still in the macular degeneration treatments developmental stages in terms of approval for commercial applications. Surgical options for dry macular degeneration are proposed periodically. The methodologies change from procedure to procedure, but the general idea is the same.
August 31st, 2010
Limited Retinal Translocation-Limited retinal translocation is another treatment aimed at wet macular degeneration. In this procedure the retina is actually moved somewhat to allow laser treatments to be applied more successfully to abnormal blood vessel growth. The procedure is still in the macular degeneration treatments developmental stages in terms of approval for commercial applications. Surgical options for dry macular degeneration are proposed periodically. The methodologies change from procedure to procedure, but the general idea is the same.
Subscribe to:
Posts (Atom)
